Clinical Trial Update: Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating safety and changes in disease activity when ABBV-927 is infused with modified FOLFIRINOX, with or without budigalimab, in untreated m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• ABBV-927
• budigalimab (budigalimab)

Snippet

Sponsor: AbbVie | Conditions: Pancreatic Cancer | Phase 1 | Status: TERMINATED